VIDEO: Options for digital rhythm, AF monitoring ‘rapidly expanding’
Click Here to Manage Email Alerts
In this video, Biykem Bozkurt, MD, PhD, the Mary and Gordon Cain Chair and Professor of Medicine at Baylor College of Medicine, discusses studies on new digital technologies presented at the American Heart Association Scientific Sessions.
One study, the REVeAL-HF trial, assessed the effects of clinical alerts sent to clinicians on the risk of adverse outcomes for patients with HF.
“Unfortunately, it didn’t demonstrate any benefit, meaning these alerts didn’t result in either optimization of guideline-directed therapies or clinical outcomes in heart failure patients, raising the question of whether increasing the alerts for clinicians is going to be really effective, and whether we should maybe reduce the number of alerts that clinicians receive,” Bozkurt, who is also director of the Winters Center for Heart Failure Research, told Healio.
She also spoke about findings from I-STOP AFib, which informed patients of their triggers for atrial fibrillation, such as caffeine intake, alcohol intake, exercise and fatigue.
“Interestingly, when the individuals were notified of their trigger, they were actually able to effectively reduce their triggers and their AF events.”
Another study, the Fitbit Heart Study, “demonstrated quite a significant efficacy in ability to detect atrial fibrillation like the smartwatches did,” Bozkurt said.
“So, from the portfolio of digital technology, we see a rapidly expanding portfolio of modalities by which we can do rhythm monitoring and detection of atrial fibrillation,” she added.
Bozkurt also discussed findings from the CRAVE study, which assessed the impact of caffeine intake and atrial and ventricular ectopy.
References:
Ahmad T, et al. REVeAL-HF: Risk Evaluation and Impact on Decision Making and Outcomes in HF.
Lubitz SA, et al. LBS.04. Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data.
Marcus GM, et al. Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial.
Marcus GM, et al. The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial. All presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).
Collapse
Click Here to Manage Email Alerts